Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies

source extracted confidence: high 2026-04-09
#hyperparathyroidism-secondary #humans #calcimimetic-agents #renal-dialysis #calcium

Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies

Nakai et al., 2024 | Ther Apher Dial | Meta Analysis

Citation

Nakai Kentaro, Kono Keiji, ... Fukagawa Masafumi. Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies. Ther Apher Dial. 2024-Aug;28(4):557-571. doi:10.1111/1744-9987.14125

Abstract

INTRODUCTION: Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis. METHODS: A systematic literature search through October 2023 and a meta-analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included. RESULTS: Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo. CONCLUSION: Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.

Key Findings

Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population secondary hyperparathyroidism undergoing dialysis
Sample Size 6371
Age Range See abstract
Condition See abstract

MeSH Terms

  • Hyperparathyroidism, Secondary
  • Humans
  • Calcimimetic Agents
  • Renal Dialysis
  • Calcium
  • Randomized Controlled Trials as Topic
  • Phosphates

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Systematic Review, Journal Article, Meta-Analysis
  • Vertical: calcium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09